Abacus acquires Swiss Cardio Technologies: the advisors
Abacus Medicine Group – a Danish group active across the modern healthcare sector – completed the acquisition of Swiss Cardio Technologies. In connection the deal Shellenberg Wittmer advised the buyer, while Baker McKenzie Switzerland represented the shareholders of Swiss Cardio Technologies.
The selling part is a spinoff from the University of Berne specialised in cardioplegia, a technique used to intentionally and temporarily interrupt cardiac activity in order to facilitate bypass surgery or other cardiac and aortic procedures.
The Shellenberg Wittmer team
The Shellenberg Wittmer team working on the matter included Oliver Triebold (pictured left), Elia Schunck, Jonas Rahm, Filip Majernik and Nanina Lätsch (all corporate/M&A), Lorenza Ferrari Hofer (pictured right) and Patrick Gürtler (both life sciences/IP), Roland Mathys and Noémi Ziegler (both ICT) and Petra Spring and Ruba Kassem (both employment).
The Baker McKenzie Switzerland team
Zurich-based partners Alexander Fischer (M&A, pictured left) and Julia Schieber (M&A, healthcare & sciences, pictured right) led the Baker McKenzie team on the matter, working alongside partner Matthias Trautmann (M&A), associate Hesam Mirzai (M&A) as well as trainee lawyers Elena Mani and Grégory Sarbach.
